Login to Your Account



Pivotal Phenserine Data Drop Axonyx's Stock By 62 Percent

By Karen Pihl-Carey


Tuesday, February 8, 2005
Axonyx Inc. lost almost two-thirds of its value on Monday with news that its lead Alzheimer's disease product, Phenserine, failed in a European Phase III trial. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription